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The direct correlation between lipoprotein (a) (Lp(a)) concentrations and atherosclerosis stimulated us to investigate the 
in vivo interaction of Lp(a) with the liver and the various liver cell types. In untreated rats the serum decay of Lp(a) 
is comparable to that of LDL. By estrogen treatment the interaction of LDL with parenchymal liver cells is increased 
l7-fold whereas only a 2-fold effect on Lp(a) is found. The decay of Lp(a) in estrogen-treated rats is slower than for 
LDL. The data indicate that Lp(a) in vivo shows a less efficient interaction than LDL with the estrogen-induced apo-B,E 
receptor on parenchymal liver cells. It is suggested that the inability of Lp(a) to interact efficiently with the LDL removal 
system of the liver might be related to its atherogenic action. 
17x-Ethinylestradiol; Lipoprotein (a); (Parenchymal liver cell, Non-parenchymal liver cell) 
1. INTRODUCTION 
Lipoprotein (a) can be detected in the blood of 
most humans. It has gained renewed interest 
because a number of studies have indicated a 
positive correlation between the serum level of 
Lp(a) and coronary vascular diseases [l-4]. 
Recently an induction of Lp(a) by fat feeding was 
reported [5]. 
After density gradient ultracentrifugation of 
human sera, Lp(a) is found in the density range of 
1.055-l. 110 g/ml which borders low density 
lipoprotein (LDL) and coincides partly with that of 
high density lipoprotein (HDL). Lp(a) resembles 
LDL in lipid composition [6] and also contains 
apo-B as the major apoprotein [7]. However, 
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Lp(a) can be distinguished from LDL by the 
presence of a unique Lp(a) apoprotein and by its 
high content of hexose, hexosamine and sialic acid 
16971. 
A number of in vitro studies have shown that 
Lp(a) can bind to the apo-B,E receptor on 
fibroblasts [g-lo], although it was also reported 
that Lp(a) does not interact with the apo-B,E 
receptor [ll]. Recently we described the in- 
trahepatic cellular localization of lipoprotein 
receptors in rats. The presence of an apo-B,E 
receptor on parenchymal and Kupffer cells [12,13] 
was demonstrated and the acetyl-LDL (scavenger) 
receptor appears to be very active on liver en- 
dothelial cells [14]. Our cell isolation method, 
which yields pure fractions of parenchymal, Kupf- 
fer or endothelial cells, now enables us to test 
which receptors are involved in the catabolism of 
Lp(a) in vivo. In order to determine the interaction 
of Lp(a) with the apo-B,E receptor, one can make 
use of the fact that the number of receptors can be 
selectively increased on parenchymal liver cells [ 121 
by estrogen treatment. 
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2. MATERIALS AND METHODS 
Human LDL (1.024 < d < 1.055 g/ml) was isolated by 2 
repetitive centrifugations according to Redgrave et al. [15] as 
described [12]. The human LDL preparation used in this study 
contains almost exclusively apolipoprotein-B (99.97%); no 
degradation products were detectable as checked by 
polyacrylamide gel electrophoresis using 2.5-25% slab gels 
with 0.1% SDS according to [ 161. With a high LDL concentra- 
tion (5 mg apolipoprotein/ml) in a radial immunodiffusion 
system according to [17], apolipoprotein-E was noticeable at 
the detection limit and contributed maximally 0.02-0.03% of 
the total apolipoprotein. 
Radioiodination of LDL was done according to the ICl 
method described in [18], using carrier-free ‘*‘I or “‘I. 
Lp(a) (1.050 < d < 1.110 g/ml) was isolated by ultracen- 
trifugation from the pooled plasma of 5-7 highly positive 
donors. Purification of Lp(a) was done according to Gaubatz 
et al. [19] with the following preservatives present during all 
steps of purification: 1 mg EDTA/ml; 0.1 mg chloram- 
phenicol/ml; 100 KIE Trasylol/ml; 10 pM phenylmethanesul- 
fonyl fluoride and 5 mM iodoacetate. Due to these preser- 
vatives, the tendency of isolated Lp(a) to precipitate upon 
cooling was kept to a minimum [20]. A typical gel pattern of 
apo-Lp(a) is shown in fig.1 and is in agreement with data 
published by Gaubatz et al. [19]. 
Radioiodination of the Lp(a) preparations was done ac- 
cording to the ICI method [18]. After iodination the Lp(a) 
preparation was dialyzed 3 times against 0.024 M NaBr, 0.01 M 
Tris-HCl, pH 8.0, and 2 times against 0.15 M NaCl, 0.3 mM 
EDTA, pH 7.0. 
Reductive methylation of the lipoproteins was done ac- 
cording to [21]. 0.5 ml lipoprotein (approx. 2.5 mg apolipopro- 
tein/ml) was mixed with 0.38 ml of 0.3 M borate buffer, pH 
9.0. At l= 0,0.5 mg NaBH4 and 0.5 ,ul formaldehyde were add- 
ed, thereafter 0.5~1 formaldehyde was added every 6 min (5 
times). The extent of methylation of lysine residues was > 80% 
as determined by the trinitrobenzenesulfonic acid method [27]. 
2.1. Animals 
12-week-old male Wistar rats were used throughout the 
study. 17a-Ethinylestradiol in propyleneglycol at a dose of 
5 mg/kg body wt [13] was injected subcutaneously every 24 h 
for 3 days. Control rats received equal volumes of the solvent. 
2.2. Materials 
17u-Ethinylestradiol was obtained from Brocacef (Maarssen, 
The Netherlands); collagenase (type I) from Sigma (St Louis, 
USA); pronase B-grade from CalBiochem-Behring (La Jolla, 
USA); metrizamide was purchased from Nyegaard (Oslo, Nor- 
way); trasylol from Bayer (Leverkusen, FRG); Ham F-10 
medium from Gibco (Paisley, Scotland) and rz51 and 13’1 
(carrier-free) from Amersham (Amersham, England). 
2.3. In vivo uptake studies 
Rats were anesthetized by intraperitoneal injection of 2 mg 
nembutal. The abdomen was opened and the radiolabeled 
lipoproteins were injected in the inferior vena cava at the level 
of the renal veins. After the indicated circulation time the liver 
was perfused with an oxygenated Hanks buffer at 8°C. After 
8 min perfusion, a lobule was tied off for determination of the 
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total liver uptake. To determine the uptake by the various cell 
types, the cell separation was carried out by low temperature 
procedures [14,23]. 
Fig. 1. Delipidated Lp(a) (2OOpg/gel) run on a non-reducing 
3.75% polyacrylamide gel containing 0.1% SDS (according to 
[191). 
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3. RESULTS 
The radiolabeled lipoproteins were injected into 
rats and after 30 min parenchymal and non- 
parenchymal cells were isolated and purified. Dur- 
ing the 30 min circulation the serum decay of the 
lipoproteins was determined (fig.2). The serum 
decay of Lp(a) is comparable to that of LDL. In 
order to determine the involvement of the paren- 
chymal apo-B,E receptor in the clearance of Lp(a), 
rats were treated with 17c+ethinylestradiol. This 
treatment accelerated the clearance rate for native 
LDL (review [12,13]), but influenced the decay of 
Lp(a) to a much lower extent. 
Fig.3A shows the in vivo uptake of Lp(a) and of 
LDL by the liver in control and estrogen-treated 
rats. It is found that the liver uptake of Lp(a) is 
enhanced by the estrogen treatment o a lesser ex- 
tent than that of LDL. In control rats the associa- 
tion of Lp(a) with the liver is higher than for LDL. 
However, the higher liver-association of Lp(a) is 
probably not LDL-receptor-mediated, since 
methylation of the lipoproteins inhibits the liver 
association of Lp(a) to a lower extent than that of 
LDL (hereby the interaction with LDL-receptors 
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can be blocked [12,13]). Fig.3B,C displays the 
amount of lipoprotein associated in vivo with the 
parenchymal and non-parenchymal cells. It is clear 
that the increased liver association of Lp(a) as 
compared to LDL is caused by an increased 
association with parenchymal cells. Estradiol 
treatment increases specifically LDL-receptors in 
parenchymal cells and therefore a 17-fold increase 
in the amount of LDL associated with paren- 
chymal cells, that can be blocked by methylation 
of the particle, is noticed. On the other hand, the 
stimulation of the Lp(a) uptake by estrogen treat- 
ment was only 2-fold while methylation of Lp(a) 
also inhibited the increased uptake in the estradiol- 
treated rats. In non-parenchymal cells the cell 
association of Lp(a) and LDL is comparable both 
in control and in estrogen-treated rats. From these 
data it can be calculated (table 1) that in control 
rats, parenchymal cells play a quantitatively more 
important role in the uptake of Lp(a) than in the 
uptake of LDL (51 versus 32%, respectively). 
After estrogen treatment he relative contribution 
of parenchymal cells to the uptake of LDL exceeds 
that of Lp(a) (90 versus 67%, respectively). 
A further subdivision of non-parenchymal cells 
5 15 25 
time (min) 
Fig.2. Serum decay of LDL (A) or Lp(a) (B) in estrogen-treated (closed symbols) and control (open symbols) rats. 3, 8, 15 and 25 min 
after injection of the “’ I-labeled lipoproteins, blood samples were drawn and the radioactivity in the serum determined. Each symbol 
represents the mean of 3-4 experiments (+ SE). 
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Fig.3. In vivo lipoprotein association with liver (A), parenchymal (B) and non-parenchymal cells (C) in control (c) and ethinylestradiol- 
treated rats (e). The radioiodinated lipoproteins were injected intravenously into rats and after 30 min of circulation, the liver cells 
were isolated. The open plus hatched bars represent association of the native lipoproteins; the hatched bars, association of reductively 
methylated lipoproteins. The values are calculated as the mean of 3-6 experiments (& SE). 
in endothelial and Kupffer cell fractions shows 
that Lp(a) has a slightly increased in vivo cell 
association with the endothelial and Kupffer cells 
as compared to LDL (table 2). However, when 
compared to the association of acetylated LDL (a 
specific substrate for the scavenger acetyl-LDL 
receptor), there is no specific increase in the uptake 
Table 1 
Percentual contribution of parenchymal and non-parenchymal 
cells to the total liver uptake of Lp(a) and LDL, 30 min after 
injection in estrogen-treated and control rats 
Table 2 
In vivo uptake of LDL, Lp(a) and acetyl-LDL in liver 
endothelial and Kupffer cells at 30 min after injection 
% injected dose x 104/mg 
cell protein 
Endothelial cells Kupffer cells 
LDL 32 + 2 (3)a 232 f 15 (3) 
Lp(a) 82 k I8 (5) 571 + 163 (5) 
Acetyl-LDLb 4700 * 500 (3) 630 f IO0 (3) 
a Mean + SE; n in parentheses 
b As shown earlier in our laboratory [I41 
Parenchymal cells 
Control Estrogen 
Non-parenchymal cells 
Control Estrogen 
by endothelial cells so that probably the acetyl- 
LDL receptor does not actively interact with Lp(a). 
Lp(a) 51 + 4 67 f 2 49 * 4 33 * 4 
LDL 32 * 3 90 t 2 68 + 6 IOk 1 
The amount of radioactivity/mg cell protein in the isolated cell 
fractions was multiplied with the amount of protein that each 
cell type contributes to total liver protein. The values are 
calculated as the mean of 4-6 experiments (+ SE) 
4. DISCUSSION 
The present study provides data on the in vivo 
interaction of Lp(a) with the liver and the various 
liver cell types. The results allow some conclusions 
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which may be relevant to an understanding of the 
atherogenic nature of this lipoprotein. (i) Lp(a) can 
interact with the apo-B,E receptor in vivo, 
although apparently less efficiently than LDL. 
This conclusion is mainly based on the modest in- 
crease in cell association to parenchymal cells upon 
estrogen treatment. These data are in accord with 
recent studies on the interaction of Lp(a) with the 
fibroblast apo-B,E receptor, which indicates that 
ape(a) can suppress the LDL character of Lp(a) 
[24]. (ii) Besides the inefficient interaction with the 
apo-B,E receptor on parenchymal cells, Lp(a) 
shows a high (unspecific) interaction with paren- 
chymal cells. This conclusion is based on the high 
association of Lp(a), as compared to LDL, with 
parenchymal cells in control rats, which is not af- 
fected by methylation. (iii) Lp(a) is not actively 
taken up by the acetyl-LDL receptor on liver en- 
dothelial cells. This indicates that in vivo Lp(a) 
does not interact with the scavenger eceptor. This 
conclusion is similar as drawn earlier from studies 
with macrophages in vitro [25]. 
The diminished interaction of Lp(a) as com- 
pared to LDL with the apo-B,E receptor of the 
liver, as noticed in estrogen-treated rats, may lead 
to a less efficient removal of Lp(a) from the cir- 
culation in animals including humans with high 
receptor activity on hepatocytes. Furthermore the 
high unspecific interaction of Lp(a) with cells 
might lead to an extracellular disposition which 
could explain the atherogenic character of this 
lipoprotein. 
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